Log in

BALAXI PHARMACEUTICALS

BALAXI· NSE
₹23.84
+₹1.17 (+5.16%) · 1Das of 12 Nov 2026, 20:33 IST

BALAXI PHARMACEUTICALS (BALAXI) last traded at ₹23.84 on NSE as of 12 Nov 2026, 20:33 IST, up 5.16% (+₹1.17) on the day. The stock is 20.3% below its 52-week high of ₹29.90 and 56.8% above its 52-week low of ₹15.20. EPS ₹0.26.

Day range₹22.70 – ₹25.55
52-week range₹15.20 – ₹29.90
Volume69,3373.56× the 20-day average
Market cap—
P/E · P/B— · —trailing
EPS₹0.26
Returns1W+8.91%1M+6.62%3M−0.87%6M−11.96%YTD—1Y—3Y—5Y—

Fundamentals

Revenue growth· latest year−7.65%
Net margin0.5%
ROE / ROA— / 0.4%
Debt-to-equity0.2×
P/E · P/B· trailing— · —
EPS₹0.26
Revenue / net income₹270 crore / ₹1 crore
Last reported year ends 31 Mar 2026

Technicals

RSI (14)68.2
20-day average· 12.5% above₹21.20
50-day average· 6.6% above₹22.37
200-day average· ——
ATR (14)· 5.76% of price₹1.37
20-session change+7.48%
Volatility· 30 sessions, annualised39.2%
From completed sessions; the RSI alone steps with the live price.

Sector today

No sector is listed for this instrument.

Latest news

All BALAXI news ↗

No publisher article about BALAXI PHARMACEUTICALS in the last 7 days.

Upcoming events

Event calendar ↗

No upcoming company event is listed for BALAXI PHARMACEUTICALS.

Frequently asked

What is the BALAXI PHARMACEUTICALS share price today?

BALAXI PHARMACEUTICALS (BALAXI) last traded at ₹23.84 on NSE as of 12 Nov 2026, 20:33 IST, up 5.16% (+₹1.17) on the day.

What is the 52-week high and low of BALAXI?

The 52-week range of BALAXI PHARMACEUTICALS is ₹15.20 to ₹29.90; the last price is 20.3% below the high.

What is the market capitalisation of BALAXI PHARMACEUTICALS?

A market capitalisation for BALAXI PHARMACEUTICALS is not available right now.

What is the P/E ratio of BALAXI PHARMACEUTICALS?

A trailing P/E for BALAXI PHARMACEUTICALS is not available right now.

What is the next scheduled event for BALAXI PHARMACEUTICALS?

No upcoming company event is listed for BALAXI PHARMACEUTICALS.

Data as of 12 Nov 2026, 20:33 IST · Research, not investment advice.